: Usage of de novo peptide sequencing, molecular docking, or total RNA sequencing (RNA-Seq) to identify malignant signatures. 3. Results and Data Analysis
: Analysis of data archived in repository files such as MM.IG.(2023).zip . MM.IG.(2023).zip
Summarize how the data in the 2023 archive supports individualized risk assessment and novel therapeutic targets in oncology. : Usage of de novo peptide sequencing, molecular
: Identification of differentially expressed genes (DEGs) and their correlation with patient survival. 4. Discussion MM.IG.(2023).zip